Reports Q4 revenue $46,280, consensus $0. "Ovid has significant momentum entering 2023. OV329, our next generation GABA-aminotransferase inhibitor program, is being actively studied in healthy volunteers. In the first half of 2024, we anticipate data characterizing OV329’s potential efficacy using a biomarker as well as its initial safety profile. In addition, Takeda is progressing the study of soticlestat in two, pivotal Phase 3 trials of patients with Dravet and Lennox-Gastaut syndromes," said Jeremy Levin, D.Phil, MB BChir., Chairman and CEO of Ovid Therapeutics. "We continue to refine our development pipeline of differentiated anti-seizure medicines while maintaining fiscal and strategic focus to drive long-term shareholder value," remarked Dr. Levin.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on OVID:
- Ovid Therapeutics Reports Business Update, Fourth Quarter and Full Year 2022 Financial Results
- Ovid Therapeutics confirms no deposits, accounts at Silicon Valley Bank
- Ovid Therapeutics announces publication of studies of OV350
- Studies Published in Cell Reports Medicine Validate the Potential of Direct KCC2 Activation in Resistant Seizures
- Ovid Therapeutics expands epilepsy development expertise
